<DOC>
	<DOC>NCT02733614</DOC>
	<brief_summary>18-week, crossover, double-blind, randomized, placebo controlled proof-of-concept study to assess the efficacy and safety of SRX246 (160 mg bid) vs placebo in 52 adult veterans and civilians with a primary diagnosis of PTSD. Subjects will be randomly assigned in a double-blind fashion to 2 groups in a crossover design. The first group will receive SRX246 for 8 weeks followed by 8 weeks of placebo, while the second group will receive placebo for 8 weeks followed by 8 weeks of SRX246. Both groups will engage in a 7-day washout period between treatments. Subjects will be assessed at baseline and then every 2 weeks during the trial using the CAPS.</brief_summary>
	<brief_title>Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD</brief_title>
	<detailed_description />
	<mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
	<mesh_term>SRX246</mesh_term>
	<criteria>Medically stable, current diagnosis of PTSD Medically unstable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>